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1. PROJECT DESCRIPTION  
It is controversial for patients with stage II colon cancer to use adjuvant chemotherapy after 
surgery. Although in theory, adjuvant chemotherapy can reduce the risk of cancer recurrence after 
surgery, many studies indicated that the improvement of adjuvant chemotherapy on survival is minimal 
for patients with stage II colon cancer. Adjuvant chemotherapy are not recommended to routine use in 
patients with stage II colon cancer; However, if patients present any high risk feature of recurrence, 
including T4 tumor, poorly/differentiated histology, lymphovascular invasion, perineural invasion, less 
than 12 lymph nodes were removed or could be assessed, positive margin, obstruction, or perforation, 
adjuvant chemotherapy can be considered to use, but it does not mean that adjuvant chemotherapy 
should be used for all stage II patients who present high-risk features. Patients with these features still 
need to talk with their doctors to decide if they can use chemotherapy or not.  Until now, there are not 
uniform standards about which part of patients with stage II colon cancer should receive adjuvant 
chemotherapy. The purpose of this study was to explore if adjuvant chemotherapy can really improve 
the survival of patients with stage II colon cancer, especially for patients who presented any high-risk 
feature of recurrence. 
 A total of 23,354 patients with stage II colon cancer and received colon cancer primary site 
surgery were selected from SEER dataset based on patient selection algorithm (Note 1). Considering that 
some patients had bad health condition and died before they could receive adjuvant chemotherapy, we 
excluded patients who survived at less than 6 months after diagnosis. We found the information of five 
high-risk features in SEER dataset, including T4 tumor, poorly/differentiated histology, perineural 
invasion, less than 12 lymph nodes were removed or could be assessed, and positive margin 
involvement (Note 2). Patients were divided into low-risk group and high-risk group according to if they 
presented any high-risk feature (Note 3). High-risk group patients were further divided into five 
subgroups (Note 4). We used 𝑥2 test to describe the characteristics of patients in low and high risk 
groups. These characteristics included five sociodemographic variables (age, gender, race, year of 
diagnosis, and urban/rural status) and five cancer-related variables (T stage, nodes examined, histology 
grades, margin involvement, and perineural invasion) (Note 5). Then, we used survival analysis (Kaplan-
Meier test and Cox regression analysis) to compare the survival difference by chemotherapy record (Yes 
vs. No/Unknown) in each risk group. For survival analysis, the primary explanatory variable was 
chemotherapy. The primary outcome variable was overall survival. The primary statistical tool is SAS 9.0. 
The univariate survival analysis reflected that no matter patients presented any high-risk feature 
or not, the survival rate of patients who received chemotherapy was obviously better than those who 
did not or unknown. This difference disappeared after multivariate survival analysis (patients’ 
sociodemographic characteristics were controlled). The possible reason was that younger patients were 
more likely to receive chemotherapy and younger patients had better survival than older patients. 
Chemotherapy did not really improve patients’ survival. We guessed that maybe for some special high-
risk features, chemotherapy could improve patients’ survival, but for some other features, 
chemotherapy could not improve patients’ survival. After analysis, we found when patients presented 
T4 tumor feature, no matter they presented any other high-risk features or not, chemotherapy could 
improve their survival. For other four high-risk features, we could not decide if chemotherapy really 
improved patients’ survival. 
  
 
2 
2. NOTES 
2.1 Patient selection algorithm in SEER dataset 
 
2.2 High-risk features of recurrence in SEER dataset 
High risk feature Seer code field  Seer code Other 
definition  
Higher T stage (T4 
versus T3) 
Derived AJCC 
T, 6th ed 
(2004+) 
T3 and T4  
Less than 12 lymph 
nodes were removed 
or could be assessed. 
Regional nodes 
examined 
(1988+) 
00-99, 
Records the total number of regional 
lymph nodes that were removed and 
examined by the pathologist.  
 
 
Poorly differentiated 
histology 
Grade Well differentiated; Grade I 
Moderately differentiated; Grade II 
Poorly differentiated; Grade III 
Undifferentiated; anaplastic; Grade IV 
 
Presence of 
lymphovascular 
invasion 
Lymph-
vascular 
Invasion 
(2004+ varying 
by schema) 
Blank(s)  
bowel obstruction or 
bowel perforation 
 
 
 
No  Obstruction: 
Medicare, 
ICD-9-CM 
Diagnosis 
Variables  Definition   
Colon cancer 
Primary Site 
Site recode ICD-O-3/WHO 2008= Colon excluding Rectum; 
Primary Site= C18.0-18.9 
Histology = 8140-8147,8210-8211,8220-8221,8260-8263,8480-8481,8490 
First malignant primary indicator=Yes 
Colon cancer stage  AJCC.Derived AJCC Stage Group, 7th ed (2010+)= 
'II','IINOS','IIA','IIB','IIC','IIEA','IIEB','IIE','IISA','IISB','IIS','IIESA','IIESB','IIES' 
Colon cancer 
primary surgery  
Surg Prim Site (1998+)=30-80 
Age  >=20 
Diagnosis year 2010-2015 
Race All race 
gender Male and Female 
Survival Month Complete data are available and there are more than 0 days of survival 
Survival Month >=6 
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 560.89, 
560.90 
Perforation: 
Medicare, 
ICD-9-CM 
Diagnosis 
569.83 
Indeterminate or 
positive margins  
 
CS site specific 
factor 6 
Circumferential 
Resection 
Margin (CRM) 
 
Positive 0-10 
Negative 11-996 (except 988) 
Unknown 998,999 
 
Presence of 
perineural invasion 
CS Site-Specific 
Factor 8 
Perineural 
Invasion 
No Presence: 0 
Presence:10 
Unknown: 988, 998, 999 
 
 
2.3 Risk group definition 
Low-risk group High-risk group 
Patients presented features: 
“T3 stage” AND  
“>=12 lymph nodes were removed or 
could be assessed” AND  
“Well or Moderately differentiated” AND  
“Negative margins” AND 
“No presence of perineural invasion” 
Patients present features: 
“T4 stage” OR 
“<12 lymph nodes were removed or could be 
assessed” OR 
“Poorly or Undifferentiated differentiated” OR 
“Positive margins” OR 
“Presence of perineural invasion” 
 
2.4 Subgroups of high-risk group 
 
Subgroup  Definition  
Subgroup 1 Patients presented high-risk feature: T4 tumor feature 
Subgroup 2 Patients presented high-risk feature: <12 lymph nodes were removed or 
could be assessed 
Subgroup 3 Patients presented high-risk feature: Poorly or undifferentiated histology 
Subgroup 4 Patients presented high-risk feature: Positive Margin 
Subgroup 5 Patients presented high-risk feature: Presence of perineural invasion 
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2.5 Characteristics of patients 
 
Sociodemographic characteristics 
(Control variables) 
Age, Gender, Race, Year of Diagnosis, and Urban/Rural 
Status 
Cancer-related characteristics  
(Stratification variables) 
T stage, nodes examined, histology grades, margin 
involvement, and perineural invasion 
 
2.6 Chemotherapy Records 
Because SEER dataset did not record the time of chemotherapy, we could not distinguish 
adjuvant and non-adjuvant of chemotherapy. However, considering that for stage II colon cancer, 
there were few patients received chemotherapy before surgery. We can consider all chemotherapy 
record in SEER dataset as adjuvant chemotherapy. We will use KCR data to check the percentage of 
adjuvant chemotherapy among all chemotherapy records. 
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3. SAS CODE 
3.1 Data Input and Format 
filename in1 'D:\Chemotherapy for stage II colon cancer\exportnew.txt'; 
ods rtf file='D:\Chemotherapy for stage II colon cancer\export.rtf'; 
*Input data; 
data casedat; 
  infile in1 LRECL = 32000 delimiter = '09'X TERMSTR = CRLF; 
  length Patient_ID $19 
    Site_recode_ICD_O_3_WHO_2008 $53 
    RX_Summ_SurgPrimSite1998 $20 
    Age_recode_with_1_year_olds $11 
    Race_recode_White_Black_Other $59 
    Sex $15 
    Year_of_Diagnosis $9 
    RuralUrban_Continuum_Code_2013 $60 
    DerivedAJCC_T_7thed2010 $9 
 Regional_nodes_examined1998 $9 
 Grade $9 
    CRM6 $60 
    Perineural_Invasion8 $9 
    Survival_months $11 
    Vitalstatusrecodestudycutoffus $5 
 Chemotherapy_Recode $5 
    ; 
  /*NOTE: skipping over field names*/ 
  if _N_ = 1 then input; 
  input Patient_ID $ 
    Site_recode_ICD_O_3_WHO_2008 $ 
    RX_Summ_SurgPrimSite1998 $ 
    Age_recode_with_1_year_olds $ 
    Race_recode_White_Black_Other $ 
    Sex $ 
    Year_of_Diagnosis $ 
    RuralUrban_Continuum_Code_2013 $ 
    DerivedAJCC_T_7thed2010 $ 
 Regional_nodes_examined1998 $ 
 Grade $ 
    CRM6 $ 
    Perineural_Invasion8 $ 
    Survival_months $ 
    Vitalstatusrecodestudycutoffus $ 
 Chemotherapy_Recode $ 
    ; 
* Label data variables; 
  label Patient_ID = "Patient ID" 
    Site_recode_ICD_O_3_WHO_2008 = "Site recode ICD-O-3/WHO 2008" 
    RX_Summ_SurgPrimSite1998 = "Surgery Record" 
    Age_recode_with_1_year_olds = "Age recode with <1 year olds" 
    Race_recode_White_Black_Other = "Race recode (White, Black, Other)" 
    Sex = "Sex" 
    Year_of_Diagnosis = "Year of Diagnosis" 
    RuralUrban_Continuum_Code_2013 = "Rural-Urban Continuum Code 2013" 
    DerivedAJCC_T_7thed2010 = "T stage" 
    Regional_nodes_examined1998 = "Lymph nodes examined" 
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    Grade=" Histology grade" 
    CRM6="Tumor Margin Involvement" 
    Perineural_Invasion8="Perineural Invasion" 
    Survival_months = "Survival months" 
    Vitalstatusrecodestudycutoffus = "Vital status recode (study cutoff 
used)" 
    Chemotherapy_Recode="Chemotherapy Record" 
    ; 
run; 
*Foramt data value; 
proc format ; 
value agegf 1='20-49' 2='50-64' 3='65-74' 4='75+'; 
value racef 1='White' 2='Black' 3='Other' 9='unknown'; 
value sexf 1="Male" 2="Female"; 
value yearf 1="2010-2011" 2="2012-2013" 3="2014-2015" ; 
value metrof 1="Metro" 2="Rural" 3="Unknown"; 
value Tstagef 1='T3 ' 2='T4' 3='Unknown'; 
value Nodesf 1='<12' 2='>=12' 3='Unknown'; 
value gradef 1="Well or Moderately differentiated" 2="Poorly or 
Undifferentiated differentiated" 3="Unknown"; 
value marginf 1="Positive resection margin" 2="Negative resection margin" 
3="unknown"; 
value invasionf 1= "No perineural invasion present" 2="Perineural invasion 
present" 3="unknown"; 
value vitalf 0='Dead' 1='Alive'; 
value chemof 0='No/Unknown' 1='Yes'; 
value riskgroupf 1='low-risk' 2='high-risk' 3='unknown'; 
*Check the orignal dataset; 
Title Orignal dataset; 
proc print data=casedat (obS=10) label; 
run; 
*Define new variables; 
data test; 
set casedat; 
format ageg agegf. race racef. gender sexf. year_group yearf. metro metrof. 
T_stage Tstagef. Lymph_Nodes Nodesf. Histology_Grade gradef. 
Margin_involvement marginf. Perineural_Invasion invasionf. vitalstatus 
vitalf. Chemotherapy chemof.  Risk_group riskgroupf. ; 
 
if 5<=Age_recode_with_1_year_olds <=10 then ageg=1; 
else if 11<=Age_recode_with_1_year_olds <=13 then ageg=2; 
else if 14<=Age_recode_with_1_year_olds <=15 then ageg=3; 
else if Age_recode_with_1_year_olds >=16 then ageg=4; 
 
race=Race_recode_White_Black_Other*1; 
gender=sex*1; 
 
if  Year_of_Diagnosis in (210,211) then year_group=1; 
else if  Year_of_Diagnosis in (212,213) then year_group=2; 
else if  Year_of_Diagnosis in (214,215) then year_group=3; 
 
if  RuralUrban_Continuum_Code_2013 in (1,2,3) then metro=1; 
else if  RuralUrban_Continuum_Code_2013 in (4,5,6,7,8,9) then  metro=2; 
else if metro=3; 
 
if DerivedAJCC_T_7thed2010=300 then T_stage=1; 
else if DerivedAJCC_T_7thed2010 in (410, 420) then T_stage=2; 
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else if T_stage=3; 
 
if 0<=Regional_nodes_examined1998<=11   then  Lymph_Nodes =1; 
else if 12<=Regional_nodes_examined1998<=90   then  Lymph_Nodes =2; 
else if Regional_nodes_examined1998>90   then  Lymph_Nodes =3; 
 
if   Grade in (1,2) then Histology_Grade=1; 
else if  Grade in (3,4) then Histology_Grade=2; 
else if  Grade =9 then Histology_Grade=3; 
 
if 0<=CRM6<=10 then Margin_involvement=1; 
else if 10<CRM6<=996 then Margin_involvement=2; 
else Margin_involvement=3; 
 
if Perineural_Invasion8="0" then Perineural_Invasion=1; 
else if Perineural_Invasion8="10" then Perineural_Invasion=2; 
else Perineural_Invasion=3; 
 
if T_stage=1 and Lymph_Nodes =2 and Histology_Grade=1 and 
Margin_involvement=2 and Perineural_Invasion=1 then Risk_group=1; 
Else if T_stage=2 or Lymph_Nodes =1 or Histology_Grade=2 or 
Margin_involvement=1 or Perineural_Invasion=2 then Risk_group=2; 
Else Risk_group=3; 
 
month_survival=Survival_months*1; 
 
if Vitalstatusrecodestudycutoffus='4' then vitalstatus=0; 
else if Vitalstatusrecodestudycutoffus='1' then vitalstatus=1; 
 
Chemotherapy=Chemotherapy_Recode*1; 
run; 
*Check the new dataset with new variables; 
Title Dataset with new defined variables; 
proc print data=test (obS=10) label; 
var Patient_ID ageg race gender  year_group  metro  T_stage  Lymph_Nodes 
Histology_Grade  Margin_involvement  Perineural_Invasion  vitalstatus  
month_survival Chemotherapy   Risk_group  ; 
run; 
 
 
3.2 Describe the Characteristics of Patients 
*Descriptive Statistics; 
Title1 Characteristics of patients undergoing surgery for stage II colon 
cancer; 
Title2 Patients in each risk feature group; 
proc freq data=test;table Risk_group * Chemotherapy / chisq; run; 
Title2 Age distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1; table ageg * Chemotherapy / chisq; 
run; 
Title2 Age distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2; table ageg * Chemotherapy / chisq; 
run; 
Title2 Gender distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1; table gender * Chemotherapy / chisq; 
run; 
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Title2 Gender distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2; table gender * Chemotherapy / chisq; 
run; 
Title2 Race distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1; table race * Chemotherapy / chisq; 
run; 
Title2 Race distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2; table race * Chemotherapy / chisq; 
run; 
Title2 Diagnosis year distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1; table year_group * Chemotherapy / 
chisq; run; 
Title2 Diagnosis year distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2; table year_group * Chemotherapy / 
chisq; run; 
Title2 Metro/rural status distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1; table metro * Chemotherapy / chisq; 
run; 
Title2 Metro/rural status distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2; table metro * Chemotherapy / chisq; 
run; 
Title2 T stage distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1;table T_stage * Chemotherapy / chisq; 
run; 
Title2 T stage distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2;table T_stage * Chemotherapy / chisq; 
run; 
Title2 Lymph_Nodes distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1;table Lymph_Nodes * Chemotherapy / 
chisq; run; 
Title2 Lymph_Nodes distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2;table Lymph_Nodes * Chemotherapy / 
chisq; run; 
Title2 Histology_Grade distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1;table Histology_Grade * Chemotherapy / 
chisq; run; 
Title2 Histology_Grade distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2;table Histology_Grade * Chemotherapy / 
chisq; run; 
Title2 Margin_involvement distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1;table Margin_involvement * 
Chemotherapy / chisq; run; 
Title2 Margin_involvement distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2;table Margin_involvement * 
Chemotherapy / chisq; run; 
Title2 Perineural_Invasion distirbution in low-risk features group; 
proc freq data=test;where Risk_Group=1;table Perineural_Invasion * 
Chemotherapy / chisq; run; 
Title2 Perineural_Invasion distirbution in high-risk features group; 
proc freq data=test;where Risk_Group=2;table Perineural_Invasion * 
Chemotherapy / chisq; run; 
 
 
3.3 Survival Analysis 
*Surival Analysis 
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*For patients in low-risk feature group, testing if chemo will influece their 
surivial; 
*Kaplan-Meier test; 
Title Patients without any high-risk of recurrence feature; 
proc lifetest data=test notable method=km ;  
time month_survival*Vitalstatus(1); 
Where Risk_group=1; 
strata Chemotherapy; 
run; 
*Kaplan-Meier test; 
PROC PHREG DATA=test;  
   class Chemotherapy (PARAM=REF REF='No/Unknown');  
Where Risk_group=1; 
MODEL month_survival*Vitalstatus(1)= Chemotherapy  /rl; 
RUN;  
*adjusted hazed ratio; 
PROC PHREG DATA=test;  
   CLASS ageg (PARAM=REF REF='20-49') race(PARAM=REF REF='White')  
gender(PARAM=REF REF='Female') year_group(PARAM=REF REF='2010-2011') 
metro(PARAM=REF REF='Rural') Chemotherapy (PARAM=REF REF='No/Unknown');  
Where Risk_group=1; 
MODEL month_survival*Vitalstatus(1)= ageg race gender year_group metro 
Chemotherapy  /rl; 
RUN;  
 
*For patients with any high risk factor,testing if chemo will influece 
surivial;  
*Kaplan-Meier test; 
Title Patients with any high-risk of recurrence feature; 
proc lifetest data=test notable method=km ;  
time month_survival*Vitalstatus(1); 
Where Risk_group=2; 
strata Chemotherapy; 
run; 
*unadjusted hazed ratio; 
PROC PHREG DATA=test;  
   CLASS   Chemotherapy (PARAM=REF REF='No/Unknown');  
Where Risk_group=2; 
MODEL month_survival*Vitalstatus(1)=  Chemotherapy  /rl; 
RUN;  
*adjusted hazed ratio; 
PROC PHREG DATA=test;  
   CLASS ageg (PARAM=REF REF='20-49') race(PARAM=REF REF='White')  
gender(PARAM=REF REF='Female') year_group(PARAM=REF REF='2010-2011') 
metro(PARAM=REF REF='Rural') Chemotherapy (PARAM=REF REF='No/Unknown');  
Where Risk_group=2; 
MODEL month_survival*Vitalstatus(1)= ageg race gender year_group metro 
Chemotherapy  /rl; 
RUN;  
 
*For patients at least with high-risk feature T4 tumor,testing if chemo will 
influece surivial;  
*Kaplan-Meier test; 
Title Patients at least with high-risk feature T4 tumor; 
proc lifetest data=test notable method=km ;  
time month_survival*Vitalstatus(1); 
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Where T_stage=2 ; 
strata Chemotherapy; 
run; 
*unadjusted hazed ratio; 
PROC PHREG DATA=test;  
  class   Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where T_stage=2; 
MODEL month_survival*Vitalstatus(1)=  Chemotherapy  /rl; 
RUN;  
*adjusted hazed ratio; 
PROC PHREG DATA=test;  
  class ageg (PARAM=REF REF='20-49') race(PARAM=REF REF='White')  
gender(PARAM=REF REF='Female') year_group(PARAM=REF REF='2010-2011') 
metro(PARAM=REF REF='Rural')  Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where T_stage=2; 
MODEL month_survival*Vitalstatus(1)= ageg race gender year_group metro  
Chemotherapy  /rl; 
RUN;  
 
*For patients at least with high-risk feature < 12 lymph nodes removed or 
assessed,testing if chemo will influece surivial;  
*Kaplan-Meier test; 
Title Patients at least with high-risk feature < 12 lymph nodes removed or 
assessed; 
proc lifetest data=test notable method=km ;  
time month_survival*Vitalstatus(1); 
Where  Lymph_Nodes =1 ; 
strata Chemotherapy; 
run; 
*unadjusted hazed ratio; 
PROC PHREG DATA=test;  
  class    Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where  Lymph_Nodes =1 ; 
MODEL month_survival*Vitalstatus(1)= Chemotherapy  /rl; 
RUN;  
*adjusted hazed ratio; 
PROC PHREG DATA=test;  
  class ageg (PARAM=REF REF='20-49') race(PARAM=REF REF='White')  
gender(PARAM=REF REF='Female') year_group(PARAM=REF REF='2010-2011') 
metro(PARAM=REF REF='Rural')  Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where  Lymph_Nodes =1 ; 
MODEL month_survival*Vitalstatus(1)= ageg race gender year_group metro  
Chemotherapy  /rl; 
RUN; 
  
*For patients at least with high-risk feature poorly/differentiated 
histology, testing if chemo will influece surivial;  
*Kaplan-Meier test; 
Title Patients at least with high-risk feature poorly/differentiated 
histology; 
proc lifetest data=test notable method=km ;  
time month_survival*Vitalstatus(1); 
Where Histology_Grade=2 ; 
strata Chemotherapy; 
run; 
*unadjusted hazed ratio; 
PROC PHREG DATA=test;  
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  class    Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where Histology_Grade=2 ; 
MODEL month_survival*Vitalstatus(1)=  Chemotherapy  /rl; 
RUN;  
*adjusted hazed ratio; 
PROC PHREG DATA=test;  
  class ageg (PARAM=REF REF='20-49') race(PARAM=REF REF='White')  
gender(PARAM=REF REF='Female') year_group(PARAM=REF REF='2010-2011') 
metro(PARAM=REF REF='Rural')  Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where Histology_Grade=2 ; 
MODEL month_survival*Vitalstatus(1)= ageg race gender year_group metro  
Chemotherapy  /rl; 
RUN;  
 
*For patients at least with high-risk feature positive margin, testing if 
chemo will influece surivial;  
*Kaplan-Meier test; 
Title Patients at least with high-risk feature positive margin; 
proc lifetest data=test notable method=km ;  
time month_survival*Vitalstatus(1); 
Where  Margin_involvement=1 ; 
strata Chemotherapy; 
run; 
*unadjusted hazed ratio; 
PROC PHREG DATA=test;  
  class  Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where  Margin_involvement=1 ; 
MODEL month_survival*Vitalstatus(1)=   Chemotherapy  /rl; 
RUN;  
*adjusted hazed ratio; 
PROC PHREG DATA=test;  
  class ageg (PARAM=REF REF='20-49') race(PARAM=REF REF='White')  
gender(PARAM=REF REF='Female') year_group(PARAM=REF REF='2010-2011') 
metro(PARAM=REF REF='Rural')  Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where  Margin_involvement=1 ; 
MODEL month_survival*Vitalstatus(1)= ageg race gender year_group metro  
Chemotherapy  /rl; 
RUN;  
 
*For patients at least with high-risk feature perineural invasion, testing if 
chemo will influece surivial;  
*Kaplan-Meier test; 
Title Patients at least with high-risk feature perineural invasion ; 
proc lifetest data=test notable method=km ;  
time month_survival*Vitalstatus(1); 
Where  Perineural_Invasion=2; 
strata Chemotherapy; 
run; 
*unadjusted hazed ratio; 
PROC PHREG DATA=test;  
  class    Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where  Perineural_Invasion=2; 
MODEL month_survival*Vitalstatus(1)=   Chemotherapy  /rl; 
RUN;  
*adjusted hazed ratio; 
PROC PHREG DATA=test;  
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  class ageg (PARAM=REF REF='20-49') race(PARAM=REF REF='White')  
gender(PARAM=REF REF='Female') year_group(PARAM=REF REF='2010-2011') 
metro(PARAM=REF REF='Rural')  Chemotherapy (PARAM=REF REF='No/Unknown'); 
Where  Perineural_Invasion=2; 
MODEL month_survival*Vitalstatus(1)= ageg race gender year_group metro  
Chemotherapy  /rl; 
RUN;  
ods rtf close; 
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4. OUTPUTS  
 
4.1 Frequency Table Outputs 
     Patients in each risk group 
 
 
 
 
Age Distribution  
 
No chemo or Unknown Chemo Total
Group 
Low-risk group 8509 1008 9517
High-risk group 7668 2692 10360
Unknown 3058 419 3477
Total 19235 4119 23354
0
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9000
Low-risk group High-risk group Unknown
Patients
No chemo or Unknown Chemo
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Age, years, % <0.0001 <0.0001
20-49 7.05 26.79 6.17 19.17
50-64 27.01 44.25 22.4 43.31
65-74 27.12 20.14 25.12 26.3
75+ 38.82 8.83 46.31 11.22
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Gender Distribution 
 
 
Race distribution 
 
0
5
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20-49 50-64 65-74 75+
Low risk group: Age
No Chemo or Unkonw (n=8509) Chemo (n=1008)
0
5
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35
40
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50
20-49 50-64 65-74 75+
High risk group: Age
No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Gender,  % 0.9785 <0.0001
Male 49.75 49.7 46.35 51.23
Female 50.25 50.3 53.65 48.77
0
10
20
30
40
50
60
Male Female
Low risk group: Gender
No Chemo or Unkonw (n=8509) Chemo (n=1008)
0
10
20
30
40
50
60
Male Female
High risk group: Gender
No Chemo or Unkonw (n=7668)
Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Race, % <0.0001 0.0044
White 79.84 73.81 81.7 79.72
Black 11.04 15.77 10.54 13
other 8.56 10.12 7.46 7.1
Unknown 0.56 0.3 0.3 0.19
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Diagnosis year distribution 
 
 
Metra/rural status distribution 
 
0
10
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40
50
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90
White Black other Unknown
Low risk group: Race
No Chemo or Unkonw (n=8509) Chemo (n=1008)
0
10
20
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40
50
60
70
80
90
White Black other Unknown
High risk group: Race
No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Year of Diagnosis, % 0.503 0.0102
2010-2011 33.66 35.42 38.81 37.3
2012-2013 36.57 35.12 36.54 35.1
2014-2015 29.77 29.46 24.65 27.6
0
5
10
15
20
25
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35
40
2010-2011 2012-2013 2014-2015
Low risk group: Diagnosis Year
No Chemo or Unkonw (n=8509) Chemo (n=1008)
0
10
20
30
40
50
2010-2011 2012-2013 2014-2015
High risk group: Diagnosis Year
No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Metro/Rural, % 0.4698 0.5606
Metro 87.3 88.1 86.92 86.48
Rural 12.7 11.9 13.08 13.52
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T stage distribution 
 
 
Nodes examined distribution 
 
0
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Metro Rural
Low risk group: Metra/Rural 
status
No Chemo or Unkonw (n=8509) Chemo (n=1008)
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High risk group: Metra/Rural 
status
No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
T Stage, % <0.0001
T3 100 100 72.08 41.05
T4 0 0 27.92 58.95
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T3 T4
Low risk group: T stage
No Chemo or Unkonw (n=8509) Chemo (n=1008)
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80
T3 T4
High risk group: T stage
No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
 Nodes Examined,% <0.0001
Nodes examined <12 0 0 27.03 21.51
Nodes examined>=12 100 100 72.85 78.27
Unknown 0 0 0.12 0.22
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Histology grades distribution 
 
 
Margin involvement distribution 
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examined>=12
Unknown
Low risk group: Nodes 
examined 
No Chemo or Unkonw (n=8509) Chemo (n=1008)
0
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Nodes
examined>=12
Unknown
High risk group: Nodes 
examined
No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Histology Grade, % <0.0001
Well or Moderately differentiated 100 100 60.42 65.9
Poorly or Undifferentiated differentiated 0 0 38.12 31.5
unknown 0 0 1.46 2.6
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differentiated
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Undifferentiated
differentiated
unknown
Low risk group: Histology Grade
No Chemo or Unkonw (n=8509) Chemo (n=1008)
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High risk group: Histology 
Grade
No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Margin involvement, % <.0001
Positve margin 0 0 20.51 21.36
Negative margin 100 100 58.06 53.16
Unknown 0 0 21.43 25.48
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Perineural Invasion distribution 
 
 
 
4.2 Survival analysis Outputs  
Patients without any high-risk factor: 
(a) KM plot (Log-Rank, P<0.0001) 
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involvement
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No Chemo or Unkonw (n=7668) Chemo (n=2692)
Stage II without any high risk factor (n=9517) Stage II with at least one high risk factor (n=10360)
Characreristic No Chemo or Unkonw (n=8509) Chemo (n=1008) P No Chemo or Unkonw (n=7668) Chemo (n=2692) P
Perineural Invasion, % 0.0092
No invasion present 100 100 76.02 73.22
Invasion present 0 0 13.02 13.97
Unknown 0 0 10.97 12.82
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Chemo (n=2692)
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(b)  Cox regression  
Unadjusted HR (Chemo Yes VS Chemo No or Unknown): 0.534, 95% CI (0.422, 0.676), P<0.0001 
 
Adjusted HR (Chemo Yes VS Chemo No or Unknown): 0.926, 95% CI (0.726, 1.180), P=0.5323  (adjusting 
age ,race, gender, year, metro/rural status) 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
Chemotherapy Yes 1 -0.62682 0.12010 27.2393 <.0001 0.534 0.422 0.676 Chemotherapy Yes 
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Patients with at least one high risk factor: 
(a) KM plot (Log-Rank, P<0.0001) 
 
(b) Cox regression  
Unadjusted HR (Chemo Yes VS Chemo No or Unknown): 0.645, 95% CI (0.576, 0.721), P<0.0001 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
ageg 50-64 1 0.85320 0.22255 14.6981 0.0001 2.347 1.517 3.631 ageg 50-64 
ageg 65-74 1 1.39953 0.21899 40.8436 <.0001 4.053 2.639 6.226 ageg 65-74 
ageg 75+ 1 2.13366 0.21486 98.6138 <.0001 8.446 5.543 12.868 ageg 75+ 
race Black 1 0.16515 0.09468 3.0428 0.0811 1.180 0.980 1.420 race Black 
race Other 1 -0.31539 0.12856 6.0183 0.0142 0.730 0.567 0.939 race Other 
race unknown 1 -11.88006 157.35897 0.0057 0.9398 0.000 0.000 6.09E128 race unknown 
gender Male 1 0.21147 0.05886 12.9100 0.0003 1.235 1.101 1.387 gender Male 
year_group 2012-2013 1 0.11492 0.06760 2.8902 0.0891 1.122 0.983 1.281 year_group 
2012-2013 
year_group 2014-2015 1 -0.08520 0.13028 0.4277 0.5131 0.918 0.711 1.185 year_group 
2014-2015 
metro Metro 1 -0.06396 0.08705 0.5398 0.4625 0.938 0.791 1.113 metro Metro 
Chemotherapy Yes 1 -0.07722 0.12364 0.3900 0.5323 0.926 0.726 1.180 Chemotherapy 
Yes 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
Chemotherapy Yes 1 -0.43915 0.05708 59.1992 <.0001 0.645 0.576 0.721 Chemotherapy Yes 
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Adjusted HR (Chemo Yes VS Chemo No or Unknown): 0.965, 95% CI (0.856, 1.088), P=0.5592 
 
Patients at least with high risk factor T4 stage 
(a) KM plot (Log-Rank, P<0.0001) 
 
(b) Cox regression  
Unadjusted HR (Chemo Yes VS Chemo No or Unknown): 0.553, 95% CI (0.478, 0.640), P<0.0001 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
ageg 50-64 1 0.24395 0.11947 4.1691 0.0412 1.276 1.010 1.613 ageg 50-64 
ageg 65-74 1 0.55168 0.11821 21.7794 <.0001 1.736 1.377 2.189 ageg 65-74 
ageg 75+ 1 1.30949 0.11378 132.4493 <.0001 3.704 2.964 4.630 ageg 75+ 
race Black 1 0.22407 0.07057 10.0818 0.0015 1.251 1.090 1.437 race Black 
race Other 1 -0.19608 0.09595 4.1762 0.0410 0.822 0.681 0.992 race Other 
race unknown 1 -0.48799 0.70784 0.4753 0.4906 0.614 0.153 2.458 race unknown 
gender Male 1 0.09963 0.04531 4.8344 0.0279 1.105 1.011 1.207 gender Male 
year_group 2012-2013 1 0.00855 0.05168 0.0274 0.8685 1.009 0.911 1.116 year_group 2012-
2013 
year_group 2014-2015 1 -0.02895 0.09494 0.0930 0.7604 0.971 0.807 1.170 year_group 2014-
2015 
metro Metro 1 0.04006 0.06611 0.3673 0.5445 1.041 0.914 1.185 metro Metro 
Chemotherapy Yes 1 -0.03569 0.06112 0.3411 0.5592 0.965 0.856 1.088 Chemotherapy 
Yes 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
Chemotherapy Yes 1 -0.59177 0.07449 63.1158 <.0001 0.553 0.478 0.640 Chemotherapy Yes 
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Adjusted HR (Chemo Yes VS Chemo No or Unknown): 0.770, 95% CI (0.656, 0.904), P=0.0014 
 
Patients at least with high risk factor <12 nodes examined: 
(a) KM plot (Log-Rank, P=0.0001) 
 
(b) Cox regression  
Unadjusted HR (Chemo Yes VS Chemo No or Unknown): 0.667, 95% CI (0.540, 0.823), P=0.0002 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
ageg 50-64 1 0.31288 0.15789 3.9271 0.0475 1.367 1.003 1.863 ageg 50-64 
ageg 65-74 1 0.53623 0.15975 11.2673 0.0008 1.710 1.250 2.338 ageg 65-74 
ageg 75+ 1 1.08962 0.15519 49.2972 <.0001 2.973 2.193 4.030 ageg 75+ 
race Black 1 0.27642 0.10396 7.0698 0.0078 1.318 1.075 1.616 race Black 
race Other 1 -0.18587 0.14301 1.6891 0.1937 0.830 0.627 1.099 race Other 
race unknown 1 -9.69975 126.02911 0.0059 0.9387 0.000 0.000 1.16E103 race unknown 
gender Male 1 -0.05273 0.06998 0.5679 0.4511 0.949 0.827 1.088 gender Male 
year_group 2012-2013 1 0.09046 0.07793 1.3475 0.2457 1.095 0.940 1.275 year_group 
2012-2013 
year_group 2014-2015 1 -0.05363 0.13928 0.1483 0.7002 0.948 0.721 1.245 year_group 
2014-2015 
metro Metro 1 0.01719 0.10096 0.0290 0.8648 1.017 0.835 1.240 metro Metro 
Chemotherapy Yes 1 -0.26121 0.08197 10.1540 0.0014 0.770 0.656 0.904 Chemotherapy 
Yes 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
Chemotherapy Yes 1 -0.40547 0.10778 14.1533 0.0002 0.667 0.540 0.823 Chemotherapy Yes 
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Adjusted HR (Chemo Yes VS Chemo No or Unknown): 0.965, 95% CI (0.772, 1.207), P=0.7543 
 
Patients at least with high risk factor poorly or undifferentiated grade: 
(a) KM plot (Log-Rank, P=0.0001) 
 
(b) Cox regression  
Unadjusted HR (Chemo Yes VS Chemo No or Unknown): 0.619, 95% CI (0.505, 0.758), P<0.0001 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
ageg 50-64 1 0.04251 0.23252 0.0334 0.8549 1.043 0.662 1.646 ageg 50-64 
ageg 65-74 1 0.41898 0.22739 3.3951 0.0654 1.520 0.974 2.374 ageg 65-74 
ageg 75+ 1 1.13423 0.21946 26.7113 <.0001 3.109 2.022 4.780 ageg 75+ 
race Black 1 0.22012 0.11868 3.4399 0.0636 1.246 0.988 1.573 race Black 
race Other 1 -0.07697 0.15238 0.2551 0.6135 0.926 0.687 1.248 race Other 
race unknown 1 0.74560 0.71236 1.0955 0.2953 2.108 0.522 8.515 race unknown 
gender Male 1 -0.02145 0.08062 0.0708 0.7902 0.979 0.836 1.146 gender Male 
year_group 2012-2013 1 -0.04996 0.09290 0.2892 0.5907 0.951 0.793 1.141 year_group 2012-
2013 
year_group 2014-2015 1 -0.16393 0.20193 0.6590 0.4169 0.849 0.571 1.261 year_group 2014-
2015 
metro Metro 1 0.00852 0.10936 0.0061 0.9379 1.009 0.814 1.250 metro Metro 
Chemotherapy Yes 1 -0.03568 0.11399 0.0980 0.7543 0.965 0.772 1.207 Chemotherapy 
Yes 
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Adjusted HR (Chemo Yes VS Chemo No or Unknown): 0.960, 95% CI (0.773, 1.192), P=0.7127 
 
Patients at least with high risk factor positive margin: 
(a) KM plot (Log-Rank, P=0.1501) 
 
(b) Cox regression  
Unadjusted HR (Chemo Yes VS Chemo No or Unknown): 0.852, 95% CI (0.684, 1.061), P=0.1520 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
Chemotherapy Yes 1 -0.48004 0.10346 21.5284 <.0001 0.619 0.505 0.758 Chemotherapy Yes 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
ageg 50-64 1 0.46560 0.22888 4.1381 0.0419 1.593 1.017 2.495 ageg 50-64 
ageg 65-74 1 0.81715 0.22399 13.3090 0.0003 2.264 1.460 3.512 ageg 65-74 
ageg 75+ 1 1.54271 0.21703 50.5263 <.0001 4.677 3.057 7.157 ageg 75+ 
race Black 1 0.24352 0.13776 3.1246 0.0771 1.276 0.974 1.671 race Black 
race Other 1 -0.26838 0.18495 2.1056 0.1468 0.765 0.532 1.099 race Other 
race unknown 1 -10.75114 179.42852 0.0036 0.9522 0.000 0.000 1.15E148 race unknown 
gender Male 1 0.13046 0.07837 2.7710 0.0960 1.139 0.977 1.329 gender Male 
year_group 2012-2013 1 -0.13460 0.08929 2.2727 0.1317 0.874 0.734 1.041 year_group 
2012-2013 
year_group 2014-2015 1 0.06194 0.14606 0.1798 0.6715 1.064 0.799 1.417 year_group 
2014-2015 
metro Metro 1 0.12760 0.11400 1.2529 0.2630 1.136 0.909 1.421 metro Metro 
Chemotherapy Yes 1 -0.04063 0.11033 0.1356 0.7127 0.960 0.773 1.192 Chemotherapy 
Yes 
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Adjusted HR (Chemo Yes VS Chemo No or Unknown): 1.196, 95% CI (0.948, 1.509), P=0.1319 
 
Patients at least with high risk factor perineural invasion present: 
(a) KM plot (Log-Rank, P=0.0101) 
 
(b) Cox regression  
Unadjusted HR (Chemo Yes VS Chemo No or Unknown): 0.0109, 95% CI (0.501, 0.914), P=0.1520 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
Chemotherapy Yes 1 -0.16026 0.11186 2.0525 0.1520 0.852 0.684 1.061 Chemotherapy Yes 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
ageg 50-64 1 0.06117 0.23454 0.0680 0.7942 1.063 0.671 1.683 ageg 50-64 
ageg 65-74 1 0.48188 0.23173 4.3244 0.0376 1.619 1.028 2.550 ageg 65-74 
ageg 75+ 1 1.21246 0.22222 29.7700 <.0001 3.362 2.175 5.197 ageg 75+ 
race Black 1 0.12782 0.15775 0.6566 0.4178 1.136 0.834 1.548 race Black 
race Other 1 -0.36529 0.22023 2.7511 0.0972 0.694 0.451 1.069 race Other 
race unknown 1 -9.75165 181.59003 0.0029 0.9572 0.000 0.000 2.16E150 race unknown 
gender Male 1 0.17380 0.09633 3.2553 0.0712 1.190 0.985 1.437 gender Male 
year_group 2012-2013 1 0.04423 0.11158 0.1571 0.6918 1.045 0.840 1.301 year_group 
2012-2013 
year_group 2014-2015 1 -0.15410 0.20025 0.5922 0.4416 0.857 0.579 1.269 year_group 
2014-2015 
metro Metro 1 0.10139 0.15354 0.4361 0.5090 1.107 0.819 1.495 metro Metro 
Chemotherapy Yes 1 0.17884 0.11870 2.2699 0.1319 1.196 0.948 1.509 Chemotherapy 
Yes 
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Adjusted HR (Chemo Yes VS Chemo No or Unknown): 0.927, 95% CI (0.672, 1.280), P=0.6473 
 
 
 
 
 
 
 
 
 
 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
Chemotherapy Yes 1 -0.39056 0.15342 6.4804 0.0109 0.677 0.501 0.914 Chemotherapy Yes 
 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Label 
ageg 50-64 1 0.27596 0.30227 0.8335 0.3613 1.318 0.729 2.383 ageg 50-64 
ageg 65-74 1 0.41672 0.30692 1.8436 0.1745 1.517 0.831 2.768 ageg 65-74 
ageg 75+ 1 1.06357 0.29077 13.3790 0.0003 2.897 1.638 5.122 ageg 75+ 
race Black 1 0.10925 0.17877 0.3734 0.5411 1.115 0.786 1.584 race Black 
race Other 1 -0.12820 0.25350 0.2557 0.6131 0.880 0.535 1.446 race Other 
race unknown 1 -10.02699 258.67270 0.0015 0.9691 0.000 0.000 6.73E215 race unknown 
gender Male 1 0.07629 0.12708 0.3604 0.5483 1.079 0.841 1.385 gender Male 
year_group 2012-2013 1 0.19132 0.14238 1.8056 0.1790 1.211 0.916 1.601 year_group 
2012-2013 
year_group 2014-2015 1 -0.47937 0.29005 2.7314 0.0984 0.619 0.351 1.093 year_group 
2014-2015 
metro Metro 1 0.24582 0.21192 1.3455 0.2461 1.279 0.844 1.937 metro Metro 
Chemotherapy Yes 1 -0.07528 0.16454 0.2094 0.6473 0.927 0.672 1.280 Chemotherapy 
Yes 
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5. RESULTS ANALYSIS 
5.1 Frequency Table Results  
23,354 patients were included in this study based on the patient selection algorithm. These 
patients were divided into low-risk feature group (n=9,517) and high-risk feature group (n=10,360). 
Additionally, 3,477 patients could not be decided into any group because of the missing values for some 
cancer-related variables. In this study, we were only interested in patients in low-risk feature group and 
high-risk feature group.  
The above bar chats compare the sociodemographic and cancer-related characteristics of 
patients by chemotherapy records within each risk group. Compared to low-risk group, the percentage 
of patients who received chemotherapy in high-risk group was obviously higher. No matter in low-risk 
feature group or high-risk feature group, compared to those who did not received chemotherapy or 
unknown, patients who received chemotherapy tended to be younger. There was not obvious 
chemotherapy record difference for different gender, race, year of diagnosis, or rural/urban status. For 
patients in high-risk group, compared to those who did not receive chemotherapy or unknown, patients 
who received chemotherapy were more likely to have T4 tumor. There was not obvious chemotherapy 
record difference for other four cancer-related characteristics. 
5.2 Survival Analysis Results 
For patients in low-risk group, Kaplan-Meier Curve (Log-Rank, P<0.0001) and unadjusted Hazard 
Ratio [0.534, 95% CI (0.422, 0.676), P<0.0001] showed that the OS of patients who received 
chemotherapy was significantly higher than those who did not or unknown. However, when controlling 
for age of diagnosis, gender, race, year of diagnosis, and rural/urban status, the adjusted HR [0.926, 95% 
CI (0.726, 1.180), P=0.5323] is not significant, indicating that there was not significant survival difference 
for patients who received chemotherapy and those who did not or unknow. 
Likewise, for patients in high risk group, patients who received chemotherapy had better 
survival than those not or unknown as the Kaplan-Meier Curve (Log-Rank, P<0.0001) and unadjusted HR 
[0.645, 95% CI (0.576, 0.721), P<0.0001] showed, but the adjusted HR [0.965, 95% CI (0.856, 1.088), 
P=0.5592] showed that this survival difference was insignificant. 
Further, for each subgroup of high-risk feature group, we found that when patients at least 
presented T4 tumor, Kaplan-Meier test (Log-Rank, P<0.0001), unadjusted HR [0.553, 95% CI (0.478, 
0.640), P<0.0001] and adjusted HR [0.770, 95% CI (0.656, 0.904), P=0.0014] consistently reflected that 
patients could benefit from Chemotherapy. Differently, for patients with positive margin, Kaplan-Meier 
test (Log-Rank, P=0.1501), unadjusted HR [0.852, 95% CI (0.684, 1.061), P=0.1520] and adjusted HR 
[1.196, 95% CI (0.948, 1.509), P=0.1319] consistently reflected that there was not significant OS 
difference for patients who received chemotherapy and those who did not or unknow. The analysis for 
other 3 high-risk features were similar: Although Kaplan-Meier test and unadjusted HR indicated that 
chemotherapy could improve OS, adjusted HR indicated this improvement was insignificant. 
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6. REPORTS (Analysis outcomes summary) 
After analysis, the following items were concluded. 
1. Younger patients were more likely to receive adjuvant chemotherapy. 
2. Patients with any high-risk features of recurrence were more likely to receive adjuvant 
chemotherapy than those without any high-risk features. 
3. When patients did not present any high-risk features of recurrence, adjuvant chemotherapy did 
not substantially improve patients’ survival. 
4. When patients presented any high-risk features of recurrence, adjuvant chemotherapy did not 
substantially improve patients’ survival. 
5. When patients presented T4 tumor, adjuvant chemotherapy substantially improved patients’ 
survival. 
6. When patients presented less than 12 lymph nodes examined, adjuvant chemotherapy did not 
substantially improve patients’ survival. 
7. When patients presented poorly/differentiated histology, adjuvant chemotherapy did not 
substantially improve patients’ survival. 
8. When patients presented less than positive margin, adjuvant chemotherapy did not 
substantially improve patients’ survival. 
9. When patients presented less than perineural invasion, adjuvant chemotherapy did not 
substantially improve patients’ survival. 
10. It is inappropriate to recommend adjuvant chemotherapy for patients with any high-risk 
features of recurrence. 
11. The presence of T4 tumor could be one indicator of using adjuvant chemotherapy. 
 
7. LESSONS   
This capstone project was a wonderful research experience for me. By reviewing the literatures, 
I learned the standard treatment of colon cancer and the high-risk features of recurrence for colon 
cancer. By using SEER dataset, I learned the ICD code of colon cancer site. By conducting data analysis, I 
reviewed the knowledge on SAS programming and survival analysis. Because of this project, I develop 
great interest in data analysis in cancer epidemiology. 
In this research experience, I realized the importance of literature review. I defined many 
variables in this project. The rationality of these new defined variables was based on other published 
literatures. In addition, I also realized that the result of data analysis is not unchanged. Even though for 
same research question, different statistical methods can lead different results. Thinking reasonable 
explanation for these different results is the key point. 
From this project, I felt that I need to learn more knowledge about biostatistics, especially some 
different statistical methods. In this research, I met the trouble of missing values. There were 3477 
patients who could not be divided into any risk group because of the missing values of some cancer 
related variables. I could not handle these patients but just simply ignored them. I desired to learn more 
statistical methods about how to handle some missing values. I also felt that I need to lean more SAS 
advanced programming knowledge, such as Macro programming. 
  
 
29 
8. PAPER DRAFT 
 
Adjuvant Chemotherapy for Patients with Stage II Colon Cancer 
ABSTRACT 
Purpose 
It is controversial for patients with stage II colon cancer to use adjuvant chemotherapy after 
surgery. Although in theory, adjuvant chemotherapy can reduce the risk of cancer recurrence after 
surgery, some studies showed that adjuvant chemotherapy had limited influence on patients’ survival 
improvement.  The purpose of this study is to explore if adjuvant chemotherapy can improve patients’ 
survival, especially for patients who presented any high-risk feature of recurrence.  
Patients and Methods 
A total of 23,354 patients with stage II colon cancer from SEER dataset were included in this 
study. Patients were divided into low-risk feature group and high-risk feature group. High-risk group 
patients were further divided into five subgroups according to the presence of different high-risk 
feature. We used 𝑥2 tests to describe the characteristics of patients. Then we used survival analysis 
(Kaplan-Meier test and Cox regression analysis) to compare the survival difference by chemotherapy 
record (Yes vs. No/Unknown) in each risk group. 
Results 
No matter in low-risk or high-risk feature group, there was not enough evidence to prove that 
chemotherapy could improve patients’ survival. However, when patients presented T4 tumor, the 
Kaplan-Meier test (Log-Rank, P<0.0001), unadjusted HR [0.553, 95% CI (0.478, 0.640), P<0.0001] and 
adjusted HR [0.770, 95% CI (0.656, 0.904), P=0.0014] consistently reflected that chemotherapy 
improved patients’ survival. For other four high-risk features, we could not prove that chemotherapy 
really improved patients’ survival. 
Conclusion 
The presence of T4 tumor is an important indicator of adjuvant chemotherapy for stage II colon 
cancer. 
INTRODCTION 
Colorectal cancer is the third most common cancer in the United States and it is also the third 
leading cause of cancer-related deaths in the US. Colorectal cancer includes colon cancer and rectal 
cancer. Compared to rectal cancer, colon cancer is more common. It is estimated that there are 97,220 
new cases of colon cancer in the US for 2018 (American Cancer Society, 2018a).  
Treatment of colon cancer is largely based on its stage. Colon cancer includes five stages: Stage 
0 is the earliest stage, and then range from Stage I to Stage IV. The treatments for stage 0 - III are 
relatively clear (stage IV means cancer has spread to distant sites, so the treatment is complex). For 
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patients in stage 0 or stage I. Surgery only is the standard treatment. For patients in stage III, Surgery 
with adjuvant chemotherapy (AC) is the standard treatment. For patients in stage II, there is no doubt 
that surgery is necessary, but the using of AC is controversial (American Cancer Society, 2018b; 
American Society of Clinical Oncology, 2004, 2017; Varghese, 2015). 
In practice, the 5-year overall survival (OS) rate for stage II patients who received surgery can 
research 80%. The main cause of cancer recurrence is that some patients may have micrometastatic 
diseases at the time of surgery, but surgery cannot recognize these diseases. In theory, AC can eradicate 
this micrometastatic disease, prevent cancer recurrence, and then improve survival, but at the same 
time, AC brings potentially serious side effects, such as tiredness, nausea, vomiting, nerve damage, and 
so on (American Society of Clinical Oncology, 2004; Varghese, 2015). Compared to its serious side 
effects, the improvement of AC on survival is very small for patients with stage II colon cancer. Some 
studies even indicated that there is not significant survival difference between stage II patients who 
received AC and those who did not (American Society of Clinical Oncology, 2004; Böckelman, 
Engelmann, Kaprio, Hansen, & Glimelius, 2015; Fang, Efron, Berho, & Wexner, 2014; O'Connor et al., 
2011; Varghese, 2015).  
Based on national and international guidelines, AC are not recommended to routine use in 
patients with stage II colon cancer, however, if patients present high risk features of recurrence, 
including T4 tumor, poorly/differentiated histology, lymphovascular invasion, perineural invasion, less 
than 12 lymph nodes were removed or could be assessed, obstruction, or perforation, AC can be 
considered, but it does not mean that AC should be used for all stage II patients who present any high-
risk features. Patients need to talk with their doctors (American Cancer Society, 2018b; American Society 
of Clinical Oncology, 2004; Varghese, 2015). Two studies indicated that even for patients with high-risk 
features, AC did not contribute to higher survival (Kucukzeybek et al., 2015; O'Connor et al., 2011). Two 
studies showed that only for patients with T4 tumor, the AC was associated with higher survival, but for 
patients with other high-risk features, there was no significant association between AC and survival 
(Kumar et al., 2014; Verhoeff, van Erning, Lemmens, de Wilt, & Pruijt, 2016). Until now, there are not 
uniform standards about which part of patients with stage II colon cancer should be given AC. More 
statistical data are needed to evaluate the benefit of AC for patients with stage II colon cancer, 
especially for those presenting high-risk features. 
In this study, the association between AC and survival are further explored among patients who 
are diagnosed as stage II colon cancer, especially for those presenting any high-risk feature. 
PATIENTS AND METHODS 
Data source 
The data came from the Surveillance, Epidemiology, and End Results (SEER) cancer database 
“Incidence -SEER 18 Regs Custom Data (with additional treatment fields), No2017 Sub (1973-215 
varying) Linked to County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, 
Surveillance Research Program, released April 2018, based on the November 2017 submission.” 
Study Population 
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All patients aged 20 years and older as well as diagnosed with primary American Joint 
Committee on Cancer (AJCC) stage II colon adenocarcinoma in a SEER area from 2010 to 2015 were 
eligible for this study. Colon Cancer were identified by site and histology codes (Primary Site=C18.0-18.9; 
Histology=8140-8147,8210-8211,8220-8221,8260-8263,8480-8481,8490) (O'Connor et al., 2011; Weiss 
et al., 2014). Further, Patients who received surgical resection of primary colon cancer were selected. 
Moreover, considering that some patients had bad health condition and died before they could receive 
AC, we excluded patients who survived at less than 6 months after diagnosis. Eventually, a total of 
23,354 patients were included in this study.  
Variables 
Outcome variable: The primary outcome variable is overall survival rate (OS), which is the 
percentage of patients who are alive for a period of time after their diagnosis. SEER Database recorded 
patients’ survival months and death/alive status. 
Explanatory variable: The primary explanatory variable is AC. AC is chemotherapy offered after 
primary site surgery with an intent of reducing the risk of cancer recurrence (American Society of Clinical 
Oncology, 2004; Kopetz, Freitas, Calabrich, & Hoff, 2008). SEER database had chemotherapy records but 
did not indicate this chemotherapy was AC or not. We used Kentucky Cancer Registry (KCR) database to 
check the percentage of patients who received chemotherapy before primary surgery and found this 
percentage is minimal.  Considering the similarity of KCR data and SEER data, we believed that most 
chemotherapy records in SEER data could be regarded as AC records. 
Stratification variables: The primary stratification variables were high risk features of recurrence. 
SEER database included the information of five high risk features (T4 tumor, poorly/differentiated 
histology, less than 12 lymph nodes removed or assessed, positive margin, perineural invasion,). The 
information of other three high risk features (lymphovascular invasion, obstruction, or perforation) was 
not recorded in SEER database. 
Control variables: The primary control variables included age of diagnosis (>=20 years old), 
gender (male and female), race (white, black, other or unknown), year of diagnosis (2010-2015), and 
urban/rural status. 
Statistical Analysis 
Patients were divided into two risk-feature groups. If patients presented any one of the five 
SEER-listed high-risk features of recurrence, they were in the high-risk features group. If they did not 
present any of the five SEER-listed high-risk features, they were in the low-risk features group. 
Then we used 𝑥2 tests to compare the frequency of patients’ sociodemographic and cancer-
related variables by chemotherapy records (Yes vs. No/Unknown) within each risk group. The 
sociodemographic variables were five control variables: age, gender, race, year of diagnosis, and 
urban/rural status. The cancer-related variables included T stage, nodes examined, histology grades, 
margin involvement, and perineural invasion. 
 Kaplan-Meier test were used to compare the OS difference by chemotherapy records (Yes vs. 
No/Unknown) within each risk-feature group. Then Cox regression analysis was used to compare the 
hazard ratio (HR) for different chemotherapy records (Yes vs. No/Unknown) within each risk-feature 
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group. Compared to patients in low-risk group, we were more interested in the effect of chemotherapy 
on patients in high-risk group because patients in high-risk group were more likely to be recommended 
to receive chemotherapy. Based on the presence of different high-risk features, the high-risk group 
patients were further divided into five subgroups: patients at least with T4 tumor, patients at least with 
poorly/differentiated histology, patients at least with less than 12 lymph nodes removed or assessed, 
patients at least with positive margin, and patients at least with perineural invasion. For each of these 
five subgroups, we repeated to conduct Kaplan-Meier test and Cox regression analysis. 
RESULTS 
Characteristics of Patients 
As described in the patients and methods section, 23,354 patients were included in this study 
based on the patient selection algorithm. These patients were divided into low-risk feature group 
(n=9,517) and high-risk feature group (n=10,360). Additionally, 3,477 patients could not be decided into 
any group because of the missing values for some cancer-related variables. In this study, we were only 
interested in patients in low-risk feature group and high-risk feature group.  
Table 1 compare the sociodemographic and cancer-related characteristics of patients by 
chemotherapy records within each risk group. Compared to low-risk group, the percentage of patients 
who received chemotherapy in high-risk group was obviously higher. No matter in low-risk feature 
group or high-risk feature group, compared to those who did not received chemotherapy or unknown, 
patients who received chemotherapy tended to be younger. There was not obvious chemotherapy 
record difference for different gender, race, year of diagnosis, or rural/urban status. For patients in high-
risk group, compared to those who did not receive chemotherapy or unknown, patients who received 
chemotherapy were more likely to have T4 tumor. There was not obvious chemotherapy record 
difference for other four cancer-related characteristics. 
Survival Benefit of Chemotherapy 
For patients in low-risk group (Figure 1), Kaplan-Meier Curve (Log-Rank, P<0.0001) and 
unadjusted Hazard Ratio [0.534, 95% CI (0.422, 0.676), P<0.0001] showed that the OS of patients who 
received chemotherapy was significantly higher than those who did not or unknown. However, when 
controlling for age of diagnosis, gender, race, year of diagnosis, and rural/urban status, the adjusted HR 
[0.926, 95% CI (0.726, 1.180), P=0.5323] is not significant, indicating that there was not significant 
survival difference for patients who received chemotherapy and those who did not or unknow. 
Likewise, for patients in high risk group (Figure 2), patients who received chemotherapy had 
better survival than those not or unknown as the Kaplan-Meier Curve (Log-Rank, P<0.0001) and 
unadjusted HR [0.645, 95% CI (0.576, 0.721), P<0.0001] showed, but the adjusted HR [0.965, 95% CI 
(0.856, 1.088), P=0.5592] showed that this survival difference was insignificant. 
Further, for each subgroup of high-risk feature group, we found that when patients at least 
presented T4 tumor, Kaplan-Meier test (Log-Rank, P<0.0001), unadjusted HR [0.553, 95% CI (0.478, 
0.640), P<0.0001] and adjusted HR [0.770, 95% CI (0.656, 0.904), P=0.0014] consistently reflected that 
patients could benefit from Chemotherapy (Figure 3). Differently, for patients with positive margin, 
Kaplan-Meier test (Log-Rank, P=0.1501), unadjusted HR [0.852, 95% CI (0.684, 1.061), P=0.1520] and 
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adjusted HR [1.196, 95% CI (0.948, 1.509), P=0.1319] consistently reflected that there was not significant 
OS difference for patients who received chemotherapy and those who did not or unknow (Figure 6). The 
analysis for other 3 high-risk features were similar (Figure 4, Figure 5, Figure 7): Although Kaplan-Meier 
test and unadjusted HR indicated that chemotherapy could improve OS, adjusted HR indicated this 
improvement was insignificant. 
DISCUSSION 
The univariate analysis reflected that no matter patients presented any high-risk feature or not, 
the survival rate for patients who received chemotherapy was obviously better than those who did not 
or unknown. This difference disappeared after patients’ sociodemographic characteristics were 
controlled. The possible reason was that younger patients were more likely to receive chemotherapy 
and younger patients had better survival than older patients. Chemotherapy did not really improve 
patients’ survival. 
Patients who presented any high-risk features of recurrence were more likely to be 
recommended to receive chemotherapy. However, in this study, even when patients presented any 
high-risk features, chemotherapy did not really improve patients’ survival. We guessed that maybe for 
some special high-risk features, chemotherapy could improve patients’ survival, but for some other 
features, chemotherapy could not improve patients’ survival. After analysis, we found when patients 
presented T4 tumor feature, no matter they presented any other high-risk features or not, 
chemotherapy could improve their survival. For other four high-risk features, we could not decide if 
chemotherapy really improved patients’ survival. 
In this analysis, the data was the information of patients diagnosed as colon adenocarcinoma 
from 2010 to 2015. This data is the newest data for colon cancer in SEER database. From 2010, the 
information of margin involvement and perineural invasion became available. Few previous studies 
involved these two factors. The other advantage of this study was that the age range. Some previous 
studies only involved patients aged 65 or older, but this study included younger patients (O'Connor et 
al., 2011; Weiss et al., 2014). 
Because SEER data did not include the information of perineural invasion, obstruction, and 
perforation. The definition of risk group was not precise, and we could not test the effects of these three 
features.  SEER data recorded chemotherapy as “Yes” and “No/Unknow”, which also influenced the 
accuracy of analysis. In addition, SEER data did not record the time of chemotherapy, thus we could not 
precisely distinguish the adjuvant chemotherapy and non-adjuvant chemotherapy.  Two solutions for 
these limitations were to use SEER-Medicare data or KCR data. However, SEER-Medicare data lacked the 
information of patients aged <65. KCR data for stage II colon cancer was too small to impactable. Further 
analysis needs more advanced database. 
CONCLUSIONS 
For patients with stage II colon cancer, chemotherapy improved the overall survival for those presented 
T4 tumor feature, no matter they presented any other high-risk features or not. The presence of T4 
tumor was an important indicator of chemotherapy for stage II colon cancer. 
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Table 1. Characteristics of Patients Undergoing Surgery for Stage II Colon Cancer 
  Stage II without any high-risk features 
(n=9,517) 
 
Stage II with any high-risk feature 
(n=10,360) 
  
Characteristics No Chemo or 
Unknow (n=8,509) 
Chemo 
(n=1,008) 
P No Chemo or 
Unknow (n=7,668) 
Chemo 
(n=2,692) 
P 
Age, years, % 
  
<0.0001 
  
<0.0001 
20-49 7.05 26.79 
 
6.17 19.17   
50-64 27.01 44.25 
 
22.4 43.31   
65-74 27.12 20.14 
 
25.12 26.3   
75+ 38.82 8.83 
 
46.31 11.22   
Gender, % 
  
0.9785 
  
<0.0001 
Male 49.75 49.7 
 
46.35 51.23   
Female 50.25 50.3 
 
53.65 48.77   
Race, % 
  
<0.0001 
  
0.0044 
White 79.84 73.81 
 
81.7 79.72   
Black  11.04 15.77 
 
10.54 13   
other 8.56 10.12 
 
7.46 7.1   
Unknown 0.56 0.3 
 
0.3 0.19   
Year of Diagnosis, % 
  
0.503 
  
0.0102 
2010-2011 33.66 35.42 
 
38.81 37.3   
2012-2013 36.57 35.12 
 
36.54 35.1   
2014-2015 29.77 29.46 
 
24.65 27.6   
Metro/Rural, % 
  
0.4698 
  
0.5606 
Metro 87.3 88.1 
 
86.92 86.48   
Rural 12.7 11.9 
 
13.08 13.52   
T Stage, % 
     
<0.0001 
T3 100 100 
 
72.08 41.05   
T4 0 0 
 
27.92 58.95   
 Nodes Examined, % 
     
<0.0001 
<12 0 0 
 
27.03 21.51   
>=12 100 100 
 
72.85 78.27   
Unknown 0 0 
 
0.12 0.22   
Histology Grade, % 
     
<0.0001 
Well or Moderately 
differentiated 
100 100 
 
60.42 65.9   
Poorly or 
Undifferentiated 
differentiated 
0 0 
 
38.12 31.5   
unknown 0 0 
 
1.46 2.6   
Margin 
involvement, % 
     
<.0001 
Positive 0 0 
 
20.51 21.36   
Negative 100 100 
 
58.06 53.16   
Unknown 0 0 
 
21.43 25.48   
Perineural 
Invasion, % 
     
0.0092 
No invasion present 100 100 
 
76.02 73.22   
Invasion present 0 0 
 
13.02 13.97   
Unknown 0 0   10.97 12.82   
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Figure 1. The effects of adjuvant chemotherapy on overall survival for patients without any high-risk feature 
 
Figure 2. The effects of adjuvant chemotherapy on overall survival for patients with any high-risk feature 
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Figure 3. The effects of adjuvant chemotherapy on overall survival for patients at least with T4 tumor  
 
Figure 4. The effects of adjuvant chemotherapy on overall survival for patients at least with < 12 lymph nodes removed or 
assessed 
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Figure 5. The effects of adjuvant chemotherapy on overall survival for patients at least with poorly/differentiated histology 
 
Figure 6. The effects of adjuvant chemotherapy on overall survival for patients at least with positive margin 
  
 
38 
 
Figure 7. The effects of adjuvant chemotherapy on overall survival for patients at least with perineural invasion 
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9. Defense Presentation  
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